BBNX
BEARISH
$15.96
Live
Beta Bionics, Inc. · NASDAQ
Target $31.8
(+99.2%)
$8.89
52W Range
$32.71
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$702.63M
P/E
N/A
ROE
-47.5%
Profit margin
-87.9%
Debt/Equity
0.03
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
78%
BBNX exhibits a critically weak Piotroski F-Score of 1/9, indicating severe financial distress, and lacks an Altman Z-Score, preventing a full solvency assessment. Despite strong revenue growth of 63.1% YoY and a robust gross margin of 54.51%, the company is deeply unprofitable with negative operating and net margins, deteriorating earnings, and a negative Forward P/E of -9.72. Insider selling worth $1.32M over the past six months and a bearish technical trend of 0/100 further signal lack of confidence. While analysts maintain a strong_buy consensus with a $31.80 target price, the current fundamentals and cash flow opacity suggest substantial risk.
Key Strengths
Exceptional year-over-year revenue growth of 63.10%, significantly above sector average of 38.87%
High gross margin of 54.51%, indicating strong pricing power or cost control in core operations
Exceptionally strong liquidity position with a current ratio of 10.64 and quick ratio of 9.57
Very low debt/equity ratio of 0.03, suggesting minimal leverage risk
Analyst consensus is strong_buy with a high target price of $31.80, implying 99% upside
Key Risks
Critically low Piotroski F-Score of 1/9, signaling severe financial weakness and high risk of continued underperformance
Deeply negative profitability: -87.89% profit margin and -47.52% ROE indicate ongoing losses and poor capital efficiency
Negative Forward P/E of -9.72 reflects unprofitability and uncertainty in future earnings trajectory
Insiders have sold $1.32M in shares with zero buys in the last 6 months, signaling bearish sentiment from management
Extreme volatility and poor price performance: -48.7% in the last month and -32.5% over the past year despite recent 6M rebound
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
25
Weak
20
65
25
15
0
AI Verdict
High-risk speculative position with unproven profitability and conflicting signals between growth and financial health
Key drivers: Piotroski F-Score of 1/9, Negative earnings and margins, Strong revenue growth, Insider selling, Analyst optimism
Confidence
85%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Low P/B of 2.38 relative to unprofitable peers
Watchpoints
- Forward P/E of -9.72 indicates unprofitability
- No Graham Number or intrinsic value available
- Price/Sales of 7.93 is high for a loss-making company
Future
65/100
Ref Growth rates
Positives
- 63.10% YoY revenue growth well above sector average
- Analyst target price implies strong future upside
Watchpoints
- Earnings growth is negative and volatile
- Q/Q EPS growth declined by 22.2%
Past
25/100
Ref Historical trends
Positives
- Some quarters beat earnings estimates (2 out of 4)
Watchpoints
- Average earnings surprise of -7.51%
- Recent quarters show large negative surprises (e.g., -123.6%)
- 1Y, 3Y, and 5Y returns all at -32.5%
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 10.64 and quick ratio of 9.57 indicate strong short-term liquidity
- Debt/Equity of 0.03 shows minimal financial leverage
Watchpoints
- Piotroski F-Score of 1/9 indicates critical financial weakness
- No Altman Z-Score available for solvency assessment
- ROE of -47.52% and ROA of -20.08% reflect poor asset and equity efficiency
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength of 0/100
- No dividend yield or payout history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$15.96
Analyst Target
$31.8
Upside/Downside
+99.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BBNX and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BBNX
Beta Bionics, Inc.
Primary
|
-32.5% | -32.5% | -32.5% | +7.5% | -48.7% | -13.7% |
|
EHAB
Enhabit, Inc.
Peer
|
-45.0% | +11.0% | +78.4% | +60.5% | +0.5% | +0.1% |
|
PSNL
Personalis, Inc.
Peer
|
-68.6% | +152.1% | +111.0% | -26.3% | -3.3% | +11.8% |
|
GYRE
Gyre Therapeutics, Inc.
Peer
|
-40.0% | +134.6% | +1.4% | -7.2% | -11.3% | +3.8% |
|
PRME
Prime Medicine, Inc.
Peer
|
-75.2% | -72.0% | +207.3% | -30.1% | +7.9% | +11.1% |
BBN
Beta Bionics, Inc.
Primary
5Y
-32.5%
3Y
-32.5%
1Y
-32.5%
6M
+7.5%
1M
-48.7%
1W
-13.7%
EHA
Enhabit, Inc.
Peer
5Y
-45.0%
3Y
+11.0%
1Y
+78.4%
6M
+60.5%
1M
+0.5%
1W
+0.1%
PSN
Personalis, Inc.
Peer
5Y
-68.6%
3Y
+152.1%
1Y
+111.0%
6M
-26.3%
1M
-3.3%
1W
+11.8%
GYR
Gyre Therapeutics, Inc.
Peer
5Y
-40.0%
3Y
+134.6%
1Y
+1.4%
6M
-7.2%
1M
-11.3%
1W
+3.8%
PRM
Prime Medicine, Inc.
Peer
5Y
-75.2%
3Y
-72.0%
1Y
+207.3%
6M
-30.1%
1M
+7.9%
1W
+11.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-9.72
PEG Ratio
N/A
P/B Ratio
2.38
P/S Ratio
7.93
EV/Revenue
5.44
EV/EBITDA
-7.15
Market Cap
$702.63M
Profitability
Profit margins and return metrics
Profit Margin
-87.89%
Operating Margin
-62.54%
Gross Margin
54.51%
ROE
-47.52%
ROA
-20.08%
Growth
Revenue and earnings growth rates
Revenue Growth
+63.1%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.03
Low debt
Current Ratio
10.64
Strong
Quick Ratio
9.57
Excellent
Cash/Share
$5.2
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-17
$N/A
2025-10-28
$-0.33
+19.8% surprise
2025-07-29
$-0.27
+41.4% surprise
2025-05-06
$-0.93
-83.8% surprise
Healthcare Sector Comparison
Comparing BBNX against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-47.52%
This Stock
vs
-88.14%
Sector Avg
-46.1%
(Below Avg)
Profit Margin
-87.89%
This Stock
vs
-16.28%
Sector Avg
+439.9%
(Superior)
Debt to Equity
0.03
This Stock
vs
2.66
Sector Avg
-99.0%
(Less Debt)
Revenue Growth
63.1%
This Stock
vs
124.04%
Sector Avg
-49.1%
(Slower)
Current Ratio
10.64
This Stock
vs
4.47
Sector Avg
+137.7%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BBNX
Beta Bionics, Inc.
|
BEARISH | $702.63M | - | -47.5% | -87.9% | $15.96 | |
|
EHAB
Enhabit, Inc.
|
BEARISH | $703.84M | - | -0.5% | -0.4% | $13.74 | Compare |
|
PSNL
Personalis, Inc.
|
BEARISH | $704.48M | - | -35.0% | -116.7% | $6.73 | Compare |
|
GYRE
Gyre Therapeutics, Inc.
|
BEARISH | $711.9M | 369.5 | 8.2% | 4.3% | $7.39 | Compare |
|
PRME
Prime Medicine, Inc.
|
BEARISH | $687.9M | - | -146.8% | -% | $3.81 | Compare |
BBNX
Beta Bionics, Inc.
BEARISH
Mkt Cap
$703M
P/E
-
ROE
-47.5%
Price
$15.96
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-13 | MICHEL GERARD J | Director | Stock Award | 3,997 | - |
| 2026-01-13 | CARNEY SEAN D | Director | Stock Award | 3,997 | - |
| 2026-01-13 | DEAREN DANNY L | Director | Stock Award | 3,997 | - |
| 2026-01-13 | PALASIS MARIA | Director | Stock Award | 3,997 | - |
| 2026-01-13 | LEZACK ADAM | Director | Stock Award | 3,997 | - |
| 2026-01-13 | JONES CHRISTY | Director | Stock Award | 3,997 | - |
| 2026-01-06 | MENSINGER MIKE | Officer | Sale | 2,200 | $66,221 |
| 2026-01-02 | FEIDER STEPHEN | Chief Financial Officer | Option Exercise | 20,000 | $102,000 |
| 2026-01-02 | FEIDER STEPHEN | Chief Financial Officer | Sale | 20,000 | $590,680 |
| 2026-01-02 | MENSINGER MIKE | Officer | Sale | 7,800 | $230,950 |
| 2025-12-02 | SAINT SEAN | Chief Executive Officer | Sale | 3,278 | $96,163 |
| 2025-12-02 | FEIDER STEPHEN | Chief Financial Officer | Sale | 1,427 | $41,862 |
| 2025-12-02 | MENSINGER MIKE | Officer | Sale | 1,063 | $31,184 |
| 2025-12-01 | PALASIS MARIA | Director | Sale | 1,406 | $41,552 |
| 2025-12-01 | LEZACK ADAM | Director | Sale | 1,406 | $41,543 |
MICHEL GERARD J
Director
2026-01-13
3,997 shares
CARNEY SEAN D
Director
2026-01-13
3,997 shares
DEAREN DANNY L
Director
2026-01-13
3,997 shares
PALASIS MARIA
Director
2026-01-13
3,997 shares
LEZACK ADAM
Director
2026-01-13
3,997 shares
JONES CHRISTY
Director
2026-01-13
3,997 shares
MENSINGER MIKE
Officer
2026-01-06
2,200 shares
·
$66,221
FEIDER STEPHEN
Chief Financial Officer
2026-01-02
20,000 shares
·
$102,000
FEIDER STEPHEN
Chief Financial Officer
2026-01-02
20,000 shares
·
$590,680
MENSINGER MIKE
Officer
2026-01-02
7,800 shares
·
$230,950
SAINT SEAN
Chief Executive Officer
2025-12-02
3,278 shares
·
$96,163
FEIDER STEPHEN
Chief Financial Officer
2025-12-02
1,427 shares
·
$41,862
MENSINGER MIKE
Officer
2025-12-02
1,063 shares
·
$31,184
PALASIS MARIA
Director
2025-12-01
1,406 shares
·
$41,552
LEZACK ADAM
Director
2025-12-01
1,406 shares
·
$41,543
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
10 analysts
Lake Street
2026-01-09
Buy
Buy
B of A Securities
2026-01-05
Buy
Buy
Truist Securities
2025-12-18
Buy
Buy
Goldman Sachs
2025-10-29
Buy
Buy
Stifel
2025-10-29
Buy
Buy
Truist Securities
2025-10-29
Buy
Buy
Piper Sandler
2025-10-29
Overweight
Overweight
Goldman Sachs
2025-10-01
Neutral
Buy
Truist Securities
2025-09-22
Buy
Buy
Truist Securities
2025-07-30
Buy
Buy
Past News Coverage
Recent headlines mentioning BBNX from our newsroom.
Newest → oldest
No matching news yet.